GlassScriptPhysician profile
Herminio Balderama
NPI 1861433377
$1,513.28
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,350 · 2020: $163.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $314.49 | 2019-2020 | |
| Pfizer INC. | $236.15 | 2019-2020 | |
| Novo Nordisk INC | $202.44 | 2019 | |
| Amarin Pharma, INC. | $131.80 | 2019 | |
| Janssen Pharmaceuticals, INC | $99.08 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $93.43 | 2019 | |
| Sunovion Pharmaceuticals INC. | $75.82 | 2019 | |
| Mylan Specialty L.P. | $73.83 | 2019 | |
| Allergan, INC. | $70.71 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.67 | 2019 | |
| Merck Sharp & Dohme LLC | $57.83 | 2019-2020 | |
| Medtronic Vascular, INC. | $46.82 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.60 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.10 | 2019 | |
| Dexcom, INC. | $11.51 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Herminio Balderama listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.